FDA Clearance Tracker · P100020-S055
cobas HPV Test
Last checked: Nov 20, 2026Latest source record: May 14, 2024 (this decision)Source: openFDAMethods & limitations
Decided
May 14, 2024
Approved
Time to decision
372 days
Received May 8, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P100020-S055
- Device name
- cobas HPV Test
- Applicant
- Roche Molecular Systems, Inc.
- Applicant location
- Pleasanton, CA
- Received
- May 8, 2023
- Decided
- May 14, 2024
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P100020
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for using self-collected vaginal specimens, obtained in a healthcare setting, which can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained.
Source documents
Other decisions for Roche Molecular Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260045 · Decided Aug 28, 2026 · 233 days after receipt
Device type: C. Difficile Toxin Gene Amplification Assay (OZN) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.